Menu Search
Equities

ImmuneOnco Biopharmaceuticals Shanghai Inc

R9Z:DEU

ImmuneOnco Biopharmaceuticals Shanghai Inc

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year ImmuneOnco Biopharmaceuticals Shanghai Inc had revenues fall -28.25% from 538.00k to 386.00k, though the company grew net income from a loss of 402.89m to a smaller loss of 379.46m.
Gross margin--
Net profit margin-99,307.43%
Operating margin-98,692.04%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in CNYView more

In 2023, cash reserves at ImmuneOnco Biopharmaceuticals Shanghai Inc fell by 328.23m. Cash Flow from Financing totalled 331.04m or 85,760.36% of revenues. In addition the company used 367.55m for operations while cash used for investing totalled 294.85m.
Cash flow per share-1.06
Price/Cash flow per share--
Book value per share1.75
Tangible book value per share1.75
More ▼

Balance sheet in CNYView more

ImmuneOnco Biopharmaceuticals Shanghai Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.86
Quick ratio--
Total debt/total equity0.1628
Total debt/total capital0.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.